Amylin Pharmaceuticals, Inc. (Nasdaq:AMLN) will be presenting at the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5 at 1:30 p.m. ET/10:30 a.m. PT in New York and at the Goldman Sachs 33rd Annual Global Healthcare Conference on Wednesday, June 6 at 2:20 p.m. ET/11:20 a.m. PT in Rancho Palos Verdes, California. Mark G. Foletta, senior vice president, finance and chief financial officer of Amylin, will provide a corporate overview at the Jeffries conference. Daniel M. Bradbury, president and chief executive officer of Amylin, will provide a corporate overview at the Goldman Sachs conference.

The presentations will be webcast through the "Investors" section of Amylin's corporate website at www.amylin.com and a recording will be made available following the event. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin is committed to delivering novel therapies that transform the way diabetes and other metabolic disorders are treated. Amylin is headquartered in San Diego, Calif., and has a commercial manufacturing facility in Ohio. More information on Amylin Pharmaceuticals is available at www.amylin.com.

Amylin Pharmaceuticals, Inc.
Investors
Christine Everett-Zedelmayer
858-458-8517
christine.everett@amylin.com
or
Media
Alice Izzo
858-642-7272
alice.izzo@amylin.com